NeuMoDx random access molecular diagnostic system for detection and quantification of hepatitis B virus in clinical samples
Introduction: Currently, several molecular assays are available to detect and quantify HBV DNA in clinical samples. We aimed to characterize and compare the clinical performance of newly designed NeuMoDx PCR to the existing artus PCR. Methodology: The plasma HBV DNA levels of 96 clinical and 5 e...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Journal of Infection in Developing Countries
2020-10-01
|
| Series: | Journal of Infection in Developing Countries |
| Subjects: | |
| Online Access: | https://jidc.org/index.php/journal/article/view/12659 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850035629957578752 |
|---|---|
| author | Ayse Arikan Murat Sayan Osman Doluca |
| author_facet | Ayse Arikan Murat Sayan Osman Doluca |
| author_sort | Ayse Arikan |
| collection | DOAJ |
| description |
Introduction: Currently, several molecular assays are available to detect and quantify HBV DNA in clinical samples. We aimed to characterize and compare the clinical performance of newly designed NeuMoDx PCR to the existing artus PCR.
Methodology: The plasma HBV DNA levels of 96 clinical and 5 external quality control samples were measured by NeuMoDx and artus assays simultaneously in Kocaeli University, Turkey. The linearity, agreement and the correlation between two assays were determined by Deming regression analysis, Bland-Altman plotting, the chi-square and the relative absolute error statistical analyzes. For all statistical analyzes, the XLSTAT statistical program was used.
Results: The mean (standard deviation; SD) age was 45.07 ± 12.29. HBsAg S/Co median (range) was 4,273.4 ± 1,138.1 and ALT U/L median (range) was 27 ± 16. The mean (SD) of HBV DNA was 1.46+E6 ± 1.0+E4 for NeuMoDx and 1.54+E5 ± 4.7 + E4 for artus assays. The Deming regression indicates a linear correlation (95% confidence). The chi-square test indicates strong correlation (p < 0.001). Bland-Altman analysis confirms that the measurement difference is acceptable. The relative absolute error analysis for artus showed relatively less and more consistent error rate. With 5 external quality check samples, the statistical significance was low (p = 0.566).
Conclusions: The NeuMoDx HBV assay showed an excellent analytical performance by providing a rapid, high throughput technology in a random-access testing system in clinical samples and may be a new solution for viral load quantification in the management of HBV infections.
|
| format | Article |
| id | doaj-art-7822cf36102f48cab35b7a7721baa5bd |
| institution | DOAJ |
| issn | 1972-2680 |
| language | English |
| publishDate | 2020-10-01 |
| publisher | The Journal of Infection in Developing Countries |
| record_format | Article |
| series | Journal of Infection in Developing Countries |
| spelling | doaj-art-7822cf36102f48cab35b7a7721baa5bd2025-08-20T02:57:25ZengThe Journal of Infection in Developing CountriesJournal of Infection in Developing Countries1972-26802020-10-01141010.3855/jidc.12659NeuMoDx random access molecular diagnostic system for detection and quantification of hepatitis B virus in clinical samplesAyse Arikan0Murat Sayan1Osman Doluca2Department of Medical Microbiology and Clinical Microbiology, Faculty of Medicine, Near East University, Nicosia, Northern CyprusPCR Unit, Educational and Research Hospital of Kocaeli, Kocaeli University, Kocaeli, TurkeyDepartment of Biomedical Engineering, Izmir University of Economics, Izmir, Turkey Introduction: Currently, several molecular assays are available to detect and quantify HBV DNA in clinical samples. We aimed to characterize and compare the clinical performance of newly designed NeuMoDx PCR to the existing artus PCR. Methodology: The plasma HBV DNA levels of 96 clinical and 5 external quality control samples were measured by NeuMoDx and artus assays simultaneously in Kocaeli University, Turkey. The linearity, agreement and the correlation between two assays were determined by Deming regression analysis, Bland-Altman plotting, the chi-square and the relative absolute error statistical analyzes. For all statistical analyzes, the XLSTAT statistical program was used. Results: The mean (standard deviation; SD) age was 45.07 ± 12.29. HBsAg S/Co median (range) was 4,273.4 ± 1,138.1 and ALT U/L median (range) was 27 ± 16. The mean (SD) of HBV DNA was 1.46+E6 ± 1.0+E4 for NeuMoDx and 1.54+E5 ± 4.7 + E4 for artus assays. The Deming regression indicates a linear correlation (95% confidence). The chi-square test indicates strong correlation (p < 0.001). Bland-Altman analysis confirms that the measurement difference is acceptable. The relative absolute error analysis for artus showed relatively less and more consistent error rate. With 5 external quality check samples, the statistical significance was low (p = 0.566). Conclusions: The NeuMoDx HBV assay showed an excellent analytical performance by providing a rapid, high throughput technology in a random-access testing system in clinical samples and may be a new solution for viral load quantification in the management of HBV infections. https://jidc.org/index.php/journal/article/view/12659Chronic hepatitis Bhepatitis B virusviral loadpolymerase chain reactionplasmaregression analysis |
| spellingShingle | Ayse Arikan Murat Sayan Osman Doluca NeuMoDx random access molecular diagnostic system for detection and quantification of hepatitis B virus in clinical samples Journal of Infection in Developing Countries Chronic hepatitis B hepatitis B virus viral load polymerase chain reaction plasma regression analysis |
| title | NeuMoDx random access molecular diagnostic system for detection and quantification of hepatitis B virus in clinical samples |
| title_full | NeuMoDx random access molecular diagnostic system for detection and quantification of hepatitis B virus in clinical samples |
| title_fullStr | NeuMoDx random access molecular diagnostic system for detection and quantification of hepatitis B virus in clinical samples |
| title_full_unstemmed | NeuMoDx random access molecular diagnostic system for detection and quantification of hepatitis B virus in clinical samples |
| title_short | NeuMoDx random access molecular diagnostic system for detection and quantification of hepatitis B virus in clinical samples |
| title_sort | neumodx random access molecular diagnostic system for detection and quantification of hepatitis b virus in clinical samples |
| topic | Chronic hepatitis B hepatitis B virus viral load polymerase chain reaction plasma regression analysis |
| url | https://jidc.org/index.php/journal/article/view/12659 |
| work_keys_str_mv | AT aysearikan neumodxrandomaccessmoleculardiagnosticsystemfordetectionandquantificationofhepatitisbvirusinclinicalsamples AT muratsayan neumodxrandomaccessmoleculardiagnosticsystemfordetectionandquantificationofhepatitisbvirusinclinicalsamples AT osmandoluca neumodxrandomaccessmoleculardiagnosticsystemfordetectionandquantificationofhepatitisbvirusinclinicalsamples |